The association between the gut microbiota metabolite trimethylamine N-oxide and heart failure.

IF 4 2区生物学 Q2 MICROBIOLOGY Frontiers in Microbiology Pub Date : 2024-09-26 eCollection Date: 2024-01-01 DOI:10.3389/fmicb.2024.1440241

Zharkyn Jarmukhanov, Nurislam Mukhanbetzhanov, Samat Kozhakhmetov, Madiyar Nurgaziyev, Aliya Sailybayeva, Makhabbat Bekbossynova, Almagul Kushugulova

{"title":"The association between the gut microbiota metabolite trimethylamine N-oxide and heart failure.","authors":"Zharkyn Jarmukhanov, Nurislam Mukhanbetzhanov, Samat Kozhakhmetov, Madiyar Nurgaziyev, Aliya Sailybayeva, Makhabbat Bekbossynova, Almagul Kushugulova","doi":"10.3389/fmicb.2024.1440241","DOIUrl":null,"url":null,"abstract":"<p><p>This systematic review explores the relationship between the gut microbiota metabolite trimethylamine N-oxide (TMAO) and heart failure (HF), given the significant impact of TMAO on cardiovascular health. A systematic search and meta-analysis of peer-reviewed studies published from 2013 to 2024 were conducted, focusing on adult patients with heart failure and healthy controls. The review found that elevated levels of TMAO are associated with atherosclerosis, endothelial dysfunction, and increased cardiovascular disease risk, all of which can exacerbate heart failure. The analysis also highlights that high TMAO levels are linked to reduced left ventricular ejection fraction (LVEF) and glomerular filtration rate (GFR), further supporting TMAO's role as a biomarker in heart failure assessment. The findings suggest that interventions targeting gut microbiota to reduce TMAO could potentially benefit patients with heart failure, although further research is needed to evaluate the effectiveness of such approaches.</p>","PeriodicalId":12466,"journal":{"name":"Frontiers in Microbiology","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464299/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3389/fmicb.2024.1440241","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This systematic review explores the relationship between the gut microbiota metabolite trimethylamine N-oxide (TMAO) and heart failure (HF), given the significant impact of TMAO on cardiovascular health. A systematic search and meta-analysis of peer-reviewed studies published from 2013 to 2024 were conducted, focusing on adult patients with heart failure and healthy controls. The review found that elevated levels of TMAO are associated with atherosclerosis, endothelial dysfunction, and increased cardiovascular disease risk, all of which can exacerbate heart failure. The analysis also highlights that high TMAO levels are linked to reduced left ventricular ejection fraction (LVEF) and glomerular filtration rate (GFR), further supporting TMAO's role as a biomarker in heart failure assessment. The findings suggest that interventions targeting gut microbiota to reduce TMAO could potentially benefit patients with heart failure, although further research is needed to evaluate the effectiveness of such approaches.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肠道微生物群代谢物三甲胺 N-氧化物与心力衰竭之间的关系。

本系统综述探讨了肠道微生物群代谢物三甲胺N-氧化物（TMAO）与心力衰竭（HF）之间的关系，因为TMAO对心血管健康有重大影响。研究人员对 2013 年至 2024 年间发表的同行评审研究进行了系统检索和荟萃分析，重点关注心力衰竭成年患者和健康对照组。综述发现，TMAO 水平升高与动脉粥样硬化、内皮功能障碍和心血管疾病风险增加有关，所有这些都会加重心力衰竭。分析还强调，高水平的TMAO与左心室射血分数（LVEF）和肾小球滤过率（GFR）降低有关，进一步支持了TMAO在心衰评估中作为生物标记物的作用。研究结果表明，针对肠道微生物群采取干预措施以减少 TMAO 有可能使心力衰竭患者受益，不过还需要进一步的研究来评估此类方法的有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers in Microbiology MICROBIOLOGY-

CiteScore

7.70

自引率

9.60%

发文量

4837

审稿时长

14 weeks

期刊介绍： Frontiers in Microbiology is a leading journal in its field, publishing rigorously peer-reviewed research across the entire spectrum of microbiology. Field Chief Editor Martin G. Klotz at Washington State University is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.